Manila Times Business
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm. Designed to treat neovascular age-related macular degeneration (nAMD), the progress of GB10 marks a significant milestone in the Company's accelerating innovative drug R&D pipelin
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trusted by the Majority of Top 30 U.S. Accounting Firms, Caseware Launches Verity Agentic Pioneer Program
Just now
IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project
Just now
Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect
Just now
Innovation Labs by Identity Digital Submits DNS-Anchored Durable Identity Proposal for AI Agents to the IETF
Just now